Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

17.08 +0.27 (+1.61%)
Streaming Delayed Price Updated: 10:50 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,842,724
Open 16.78
Bid (Size) 17.07 (9)
Ask (Size) 17.08 (3)
Prev. Close 16.81
Today's Range 16.78 - 17.14
52wk Range 8.055 - 17.69
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Teva's Migraine Treatment Found Effective For Children As Young As 6
Teva Pharmaceutical's Phase 3 SPACE study reveals Ajovy's significant efficacy in preventing episodic migraines in children aged 6-17. The trial's primary endpoint was met with safety data aligning... 
Via Benzinga

Performance

YTD
+60.07%
+60.07%
1 Month
+0.71%
+0.71%
3 Month
+32.61%
+32.61%
6 Month
+48.65%
+48.65%
1 Year
+97.69%
+97.69%

More News

Read More
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Via Benzinga
Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Via Benzinga
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
Via Benzinga
3 No-Brainer Stocks to Buy With $200 Right Now
Via The Motley Fool
Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
Via Benzinga
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Dr. Reddy's Labs Stock Sees Improved Technical Strength
Via Investor's Business Daily
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Engages In Settlement Talks Over Medicare Kickback Allegations
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
What is a Bull Flag Pattern? Explanation and Examples
Via MarketBeat
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 Generic Drug Makers With Growing Runways
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.